- Home
- CAPT vs SNSE Comparison
CAPT vs SNSE Comparison
Compare CAPT & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAPT | SNSE |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | South Korea | United States |
| Employees | 98 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 12.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CAPT | SNSE |
|---|---|---|
| Price | $0.07 | $28.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $65.00 |
| AVG Volume (30 Days) | ★ 4.0M | 56.3K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.26 |
| 52 Week High | $1.93 | $36.76 |
Technical Indicators
Market Signals| Indicator | CAPT | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 24.24 | 49.52 |
| Support Level | N/A | $24.54 |
| Resistance Level | $0.61 | $35.94 |
| Average True Range (ATR) | 0.07 | 3.88 |
| MACD | -0.03 | -0.52 |
| Stochastic Oscillator | 3.27 | 46.25 |
Price Performance
Historical ComparisonAbout CAPT Captivision Inc.
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).